Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2018-03-13 |
Ideaya Biosciences (USA - CA) |
chief medical officer |
|
nomination |
Cancer - Oncology |
Nomination |
2018-03-13 |
Ideaya Biosciences (USA - CA) Cancer Research UK (UK) |
small molecule inhibitors of Poly(ADP-ribose) glycohydrolase (PARG) |
|
development |
Cancer - Oncology |
Development agreement |
2018-03-12 |
Epizyme (USA - MA) |
|
|
nomination |
Cancer - Oncology - Rare diseases |
Nomination |
2018-03-06 |
Ligand Pharmaceuticals (USA - CA) Roivant Sciences (USA - CA) |
LGD-6972 (now RVT-1502) |
type 2 diabetes |
licensing |
Metabolic diseases |
Licensing agreement |
2018-03-05 |
Boehringer Ingelheim (Germany) ViraTherapeutics (Austria) |
oncolytic virus therapy platform and VSV-GP (Vesicular Stomatitis Virus (VSV) glycoprotein (GP) |
|
development |
Cancer - Oncology |
Development agreement |
2018-03-05 |
Retrotope (USA - CA) |
vice president |
|
nomination |
Rare diseases - Genetic diseases - Neurological diseases |
Nomination |
2018-03-01 |
Iovance Biotherapeutics (USA - CA) |
member of the board of directors |
|
nomination |
Cancer - Oncology |
Nomination |
2018-02-28 |
C3J Therapeutics (USA - CA) Synthetic Genomics (USA - CA) |
engineered bacteriophage platform |
multidrug-resistant bacterial infections |
product acquisition |
Infectious diseases |
Product acquisition |
2018-02-26 |
Mereo Biopharma (UK) |
head of patient access and commercial planning |
|
nomination |
Rare diseases |
Nomination |
2018-02-22 |
Kite Pharma (USA - CA) Sangamo Therapeutics (USA - CA) |
ex vivo cell therapies in oncology using Sangamo's zinc finger nuclease (ZFN) technology platform |
|
collaboration |
Cancer - Oncology |
Collaboration agreement |
2018-02-21 |
Amicus Therapeutics (USA - NJ) |
member of the scientific advisory board |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
2018-02-21 |
Arix Bioscience (UK) Ipsen (France) |
innovative therapies |
undisclosed |
development - commercialisation |
undisclosed |
Development agreement |
2018-02-20 |
Voyager Therapeutics (USA - MA) Abbvie (USA - IL) |
vectorized antibodies directed against tau |
Alzheimer’s disease and other tau-related neurodegenerative diseases |
development - commercialisation |
Neurodegenerative diseases |
Development agreement |
2018-02-20 |
Minoryx Therapeutics (Spain) Gain Therapeutics (Switzerland) |
Site-directed Enzyme Enhancement Therapy (SEE-Tx) platform |
|
establishment of a new subsidiary in the EU |
Technology - Services |
Establishment of a new subsidiary in the EU |
2018-02-19 |
Arix Bioscience (UK) Fosun International (China) |
|
undisclosed |
development |
undisclosed |
Development agreement |
2018-02-15 |
Oxford Biomedica (UK) Bioverativ (USA - CA) |
lentiviral vectors to treat haemophilia |
hemophilia |
licensing - collaboration |
Rare diseases - Genetic diseases - Hematological diseases |
Licensing agreement |
2018-02-12 |
Sangamo Therapeutics (USA - CA) |
senior vice president |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
2018-02-12 |
Roivant Sciences (Switzerland) Poxel (France) |
imeglimin |
type 2 diabetes |
licensing |
Metabolic diseases |
Licensing agreement |
2018-02-12 |
Axovant Sciences (USA - NY) |
|
|
nomination |
Neurological diseases - CNS diseases |
Nomination |
2018-02-08 |
Arbutus Biopharma (Canada) |
|
hepatitis B |
restructuring |
Infectious diseases |
Restructuring |